Ozempic (active ingredient semaglutide) is a GLP-1 receptor agonist that is FDA approved to manage Type 2 diabetes in adults in conjunction with a reduced-calorie diet and regular exercise
For example, if a patient experiences increased gastrointestinal side effects from a GLP-1 agonist while on hormonal therapy, adjustments may be necessary to optimise comfort and therapeutic outcomes
The key is not to stop aging, but to optimize the process
56 Conclusions Obesity has been a primary target for medical and surgical therapy
Vitamin E: Protects against oxidative stress, keeping skin hydrated and youthful
Indications: Type 2 diabetes mellitus (glycemic control) Cardiovascular risk reduction in type 2 diabetes with established CVD Contraindications: Personal/family history of medullary thyroid carcinoma (MTC) Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known hypersensitivity to semaglutide or any excipient Common Side Effects: Nausea (15.8%) Diarrhea (8.5%) Vomiting (5.0%) Abdominal pain , constipation , dyspepsia Hypoglycemia (especially with sulfonylureas or insulin) Injection site reactions Serious Risks: Pancreatitis Diabetic retinopathy complications Gallbladder disease Thyroid C-cell tumors Each OZEMPIC 0.5mg (Japanese) dose is a sterile, aqueous solution containing semaglutide and several inactive components that help maintain the stability and safety of the formulation
